[ASCO 2026] Everfront Biotech Announces Latest Clinical Results for Cerebraca® Wafer, Demonstrating Potential to Reverse Brain Cancer Chemoresistance and Initiating Phase IIb/III Trial
Date: May 28, 2026
On May 29, 2026, Everfront Biotech will be presenting at the ASCO Annual Meeting in Chicago, USA! During the conference, we will proudly showcase the clinical highlights of Cerebraca® Wafer in compassionate use and officially announce a new milestone: the initiation of a Phase IIb/III international clinical trial.
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting—the world’s leading oncology conference—a research team led by Professor Clark Chen from the Warren Alpert Medical School of Brown University officially presented two abstracts on the latest clinical advancements of Everfront Biotech Inc.’s core technology, Cerebraca® Wafer. The presentations focused on its remarkable potential in treating recurrent glioblastoma (rGBM).
Breakthrough 1: Compassionate Use Demonstrates Survival Advantage and the Mechanism to “Reverse Chemoresistance”
In a compassionate use program involving 7 patients with heavily pretreated recurrent GBM, whose complex tumor locations rendered them ineligible for conventional trials, the implantation of Cerebraca® Wafer demonstrated an excellent safety profile and achieved a median overall survival (mOS) of 14.5 months. An even more significant scientific discovery revealed through tissue analysis was that the implanted novel drug induced epigenetic changes in the tumor’s MGMT promoter (shifting from unmethylated to intermediate methylation). This successfully allowed residual cancer cells that were previously chemoresistant to regain sensitivity to chemotherapy.
Breakthrough 2: Official Initiation of a Randomized Phase IIb/III International Clinical Trial
EF-API-001 has been proven to be a “multi-targeted anti-brain cancer agent” capable of simultaneously inhibiting EGFR, c-Met, PD-L1, and DNA repair mechanisms. Based on the clear survival signals and safety profile mentioned above, a randomized Phase IIb/III trial (NCT07349693) with a target enrollment of 175 patients has officially begun. The trial will evaluate the substantial benefits of “tumor resection combined with Cerebraca® Wafer implantation, followed by Temozolomide chemotherapy” on patients’ overall survival (OS).
[Everfront Biotech’s Perspective]
The latest presentations at ASCO once again scientifically validate the irreplaceability of “localized, high-concentration drug delivery” in combating malignant brain tumors. Traditional systemic administration struggles to cross the blood-brain barrier (BBB). However, by directly implanting Cerebraca® Wafer into the lesion post-surgery, it not only perfectly bypasses the barrier but also achieves multi-targeted microenvironment intervention.
Everfront Biotech will continue to partner with top-tier international CDMOs to ensure the mass production quality of this advanced formulation. As the Phase IIb/III trial advances, we are fully accelerating our international regulatory and business development efforts, dedicating ourselves to bringing a true ray of hope for brain cancer patients worldwide.
Further Reading and References:
ASCO 2026 Abstract 259238: Localized (Z)-n-butylidenephthalide biodegradable wafer as surgical adjuvant in recurrent glioblastoma for extending survival and re-sensitizing chemotherapy: A compassionate use study. [Click here to read the original article]
ASCO 2026 Abstract 266645: Resection and intracranial implant of (Z)-n‑butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial. [Click here to read the original article]
Product Highlights of Cerebraca® Wafer:
Cerebraca® Wafer is a revolutionary implantable drug designed for the localized treatment of malignant brain tumors. Developed using multiple patented innovations, the product aims to solve critical challenges in brain cancer therapy—such as chemoresistance, high cancer stem cell content, and tumor recurrence.
Cerebraca® Wafer works by targeting receptor tyrosine kinase (RTK) signaling networks, modulating tumor resistance, and counteracting PD-L1-mediated immune evasion, a common barrier to effective treatment. In Phase I/IIa trials, no drug-related adverse effects were reported. Recurrent GBM patients showed a median overall survival of 15.7 months, with RTK-high subgroups reaching up to 26.2 months—a significant improvement over the current standard of care (6–9 months).
Everfront Biotech is actively seeking strategic partnerships and licensing opportunities to co-develop this promising therapy and extend its benefits to more patients worldwide.
Introduction to Everfront Biotech Inc.:
Everfront Biotech Inc. was founded in 2010, with a focus on research and development of new drugs, specifically the screening and further development of potential small molecules for clinical study. The company’s team is responsible for all aspects of product development, from front-end potential product development to pre-clinical research, chemistry manufacturing and controls (CMC), clinical trial submissions, and clinical trial planning and execution. To date, the Everfront Biotech team has successfully applied three clinical trials: Cerebraca® Wafer (for malignant brain tumors), HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer), which have been approved for IND applications in both the United States and Taiwan.
Everfront Biotech’s new drug development is in line with national policies, and the Cerebraca® Wafer and HK-001 products were granted the certifications of biotech and new drug in 2016. The company has received the government subsidies in three science and technology projects as of 2022 from the Ministry of Economic Affairs.
